trending Market Intelligence /marketintelligence/en/news-insights/trending/elzbcww9qmxynufreyy-pg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

OncoSil plans A$12.7M institutional placement to market lead product in EU

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

OncoSil plans A$12.7M institutional placement to market lead product in EU

Australia's OncoSil Medical Ltd. plans to raise about A$12.7 million through a non-underwritten institutional placement of about 106.1 million shares.

The late-stage medical device company said the placement will be conducted in two tranches: 72.7 million shares worth about A$8.7 million first; and then, subject to shareholder approval, another 33.3 million shares worth up to A$4 million. The shares will be issued at 12 Australian cents each.

Additionally, OncoSil plans to launch a purchase plan for up to A$4 million of its shares, under which eligible shareholders can subscribe for up to A$15,000 of shares each.

The company will use proceeds to help commercialize its lead product OncoSil in the EU and expand its global pancreatic cancer clinical trials.

Wilsons Corporate Finance Ltd. is managing the institutional placement.